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Abstract
The molecular basis of a significant number of cases of isolated
growth hormone deficiency remains unknown. We describe three
sisters affected with severe isolated growth hormone deficiency and
pituitary hypoplasia caused by biallelic mutations in the RNPC3 gene,
which codes for a minor spliceosome protein required for U11/U12
small nuclear ribonucleoprotein (snRNP) formation and splicing
of U12-type introns. We found anomalies in U11/U12 di-snRNP
formation and in splicing of multiple U12-type introns in patient
cells. Defective transcripts include preprohormone convertases
SPCS2 and SPCS3 and actin-related ARPC5L genes, which are
candidates for the somatotroph-restricted dysfunction. The
reported novel mechanism for familial growth hormone deficiency
demonstrates that general mRNA processing defects of the minor
spliceosome can lead to very narrow tissue-specific consequences.
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Introduction
Familial dwarfism with isolated growth hormone (GH) deficiency
(IGHD) can be caused by mutations in GH1 and other genes
involved in GH regulation and pituitary development (Pf€affle et al,
2011). However, the molecular basis of a significant proportion of
cases remains unknown.
Removal by splicing of introns from the primary transcripts of
most human genes is an essential step in gene expression. Splicing
is performed by spliceosomes, ribonucleoprotein complexes contain-
ing numerous proteins and five small nuclear RNAs (snRNAs). Two
types of spliceosomes excise distinct classes of introns. The major
U2-dependent spliceosome processes most introns, while a small
subset (<0.5%) present in approximately 3% of human genes is
spliced by the minor U12-dependent spliceosome (Turunen et al,
2013). U12-type introns coexist with U2-type introns in the same
genes, but are normally spliced at a slower rate (Patel et al, 2002).
Mutations in the U4atac snRNA component of the minor spliceo-
some were recently shown to cause a lethal malformation syndrome
called microcephalic osteodysplastic primordial dwarfism type 1
(MOPD1) or Taybi-Linder syndrome (TALS) (Edery et al, 2011; He
et al, 2011). Here we report that mutations in a protein component
of the minor spliceosome lead to familial IGHD.
Results
Case report
Three sisters born with normal length to normal statured and
non-consanguineous parents showed severe postnatal proportion-
ate growth retardation (height 5 to 6.6 SDS at diagnosis), typi-
cal physical features of GH deficiency including delayed bone
maturation without bone dysplasia, mild microcephaly (1.1 to
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3.1 SDS for height) and otherwise normal development (Fig 1A).
GH levels after standard stimuli and basal IGF-I and IGFBP-3 lev-
els were almost undetectable. Prolactin levels were in the low-
normal range and the remaining pituitary hormone levels were
normal. Brain MRI scans showed hypoplasia of the anterior pitui-
tary (Fig 1B). Total ghrelin levels were extremely elevated with
normal acylated ghrelin levels. No other biochemical abnormalities
were found. A final diagnosis of familial IGHD with associated
pituitary hypoplasia was made. The therapeutic response to GH
replacement is excellent to date (Fig 1C), with total ghrelin levels
decreasing in all patients (27–66% of values at diagnosis; Supple-
mentary Table 1).
Mutation identification and validation
Segregation and mutational analyses discarded involvement of all
classical genes of the GH axis (Pf€affle et al, 2011). Reverse transcrip-
tion-polymerase chain reaction (RT-PCR) indicated normal amount
and sequence of GH1 transcripts. Exome analysis of one proband
revealed missense (c.1320C>A, p.P474T) and nonsense (c.1504C>T,
p.R502X) mutations in the RNPC3 gene. Sanger sequencing vali-
dated that the three affected sisters are compound heterozygous for
both mutations. The father is a heterozygous carrier of the p.R502X
mutation and the mother and unaffected sister heterozygous carriers
of the p.P474T mutation (Fig 2A). RNPC3 codes for the 65 kDa pro-
tein of the minor spliceosome. It binds to the 3′-stem-loop of U12
snRNA and is essential for integrity of U11/U12 di-snRNP that func-
tions in U12-type intron recognition (Benecke et al, 2005; Turunen
et al, 2013). RT-PCR and sequencing of RNPC3 transcripts from
patient cell RNA showed the mutated alleles to be expressed in a 2:1
(maternal:paternal) ratio, likely due to partial nonsense-mediated
decay (NMD) of paternal mRNA (Fig 2B). Both mutations are
located in the second RNA recognition motif (RRM). The p.P474T
mutation alters a highly conserved proline residue located in a turn
position between b3-strand and a2-helix (Fig 2C). Such turn posi-
tions are typically not replaceable by other amino acids (Betts &
Russell, 2003). In addition to mRNA instability due to NMD, the
p.R502X mutation deletes the last 15 C-terminal residues that are
highly conserved (Fig 2D). Due to the conservation of the affected
residues and their position within or near the C-terminal RRM, both
mutations are predicted to have deleterious effects on RNPC3 func-
tion, impairing binding to U12 snRNA that could affect U11/12 di
snRNP complex stability (Netter et al, 2009).
Minor spliceosome assembly dysfunction in lymphoblastoid cells
Native gel analysis of nuclear extracts revealed nearly complete
loss of the functional U11/U12 di-snRNP complex in patient cells
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Figure 1. Phenotypic features of probands.
A Photograph of family members showing the marked short stature of the three affected girls compared to unaffected relatives, along with other typical features of
GHD such as frontal bossing and cherubic face. Ages are shown over each girl, with the height scale on the right.
B Midline sagittal section of the brain MRI of one proband (IGHD-02). A hypoplastic pituitary is evident (red arrow) with no other brain anomaly.
C Growth chart including the anthropometric data of the three affected siblings, bone age and height showing delayed and slow basal growth and an excellent
response to GH replacement therapy (rGH).
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(Fig 3A, lanes 3,4) and appearance of a U12 snRNP complex
with slightly reduced mobility (Fig 3A, lanes 1,2; Supplementary
Fig 11a). Reduced stability of the U11/U12 complex was
confirmed in pulldown experiments (Fig 3B,C) and glycerol
gradient analyses (Supplementary Fig 11b) using whole cell
extracts. Western blot analysis of nuclear extracts showed a
significant reduction of 65K protein levels in IGHD patients
(Fig 3D).
Analysis of spliceosomal snRNA expression levels in lympho-
blastoid cells by Northern blotting revealed that, except for an
unexpected twofold increase in U4atac snRNA levels, the snRNA
levels of both minor and major snRNPs are largely unaffected
(Fig 3E,F). These results indicate that these mutations lead to
significant destabilization of the U11/U12 di-snRNP complex in
the patient cells.
Differential splicing defects of minor introns in blood cells
To test the effect of the observed U11/U12 di-snRNP complex desta-
bilization on splicing of U12-type introns, we analyzed RNAseq data
in cells from patients and controls. Of the 695 genes listed in the
U12DB harboring U12-type introns (Sheth et al, 2006; Alioto, 2007),
522 (75%) were detected at sufficient levels to allow comparisons of
cases and controls.
We quantified the splicing efficiency and intron retention of U12-
type introns with respect to U2-type introns per gene, normalized by
gene expression and established a list of 21 genes with significantly
decreased U12/U2 ratios in patient cells (Supplementary Table 2).
We also observed aberrant processing events including exon
skipping and activation of cryptic U2-type splice sites (Fig 3G, Sup-
plementary Figs 1–10).
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Figure 2. Mutation detection and predicted effects on minor spliceosome.
A Family pedigree showing that all three affected girls are compound heterozygotes for the RNPC3 mutations shown under each symbol while the unaffected parents
and sister are heterozygous carriers for one mutation.
B Sequencing of the RT-PCR product of RNPC3 from blood RNA of the eldest proband showing the p.P474T (top) and p.R502X mutations in the same amplicon, with
relatively decreased expression of the non-sense carrying allele (p.R502X).
C Schematic representation of the function of the RNPC3 gene product, U11/U12-65K protein, in RNA splicing. The 65K protein is part of a molecular bridge that links
U11 and U12 snRNPs in the intron recognition complex. The mutations may disturb binding of U12 snRNA to 65K protein. Inset indicates the positions of the
mutations (red circles) in the 3D structure of the second RRM of the 65K protein determined by X-ray crystallography (Protein Data Bank Identification, PDB-ID:
3EGN).
D Sequence alignment of the 65K protein second RRM of multiple species using ClustalW algorithm. The mutated residues (red arrows) are highly conserved
phylogenetically. (HSA: Homo sapiens; PTR: Pan troglodytes; MMU: Macaca mulatta; CAN: Canis lupus; BTA: Bos taurus; MM: Mus musculus; RN: Rattus norvegicus; GG:
Gallus gallus; DR: Danio rerio; AT: Arabidopsis thaliana; OS: Oryza sativa).
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Figure 3. U11/U12 di-snRNP stability, snRNA levels and U12-type splicing efficiency in cells from IGHD patients and controls.
A Native gel analysis of U11 and U12 snRNP complexes in nuclear extracts.
B U12 snRNP pull-down assay measuring the level of U11 snRNP associated with U12 snRNP. Three technical replicates were used for each pulldown. Students t test,
**P = 0.02, ***P = 0.01, n = 3.
C Representative gel of data in panel B.
D Western blot analysis of control and patient nuclear extracts using antibodies targeted to U11/U12-65K protein. Purified U11/U12 di-snRNP was used as control in
lane 3.
E Northern blot analysis of expression levels of spliceosomal snRNAs in lymphoblastoid cell lines from two patients (IGHD-01 and IGHD-02) and two controls
(CTRL-01 = LCL422 and CTRL-02 = LCL452). Total RNA was extracted from each cell line and individual snRNAs detected by Northern blotting.
F Quantification of the snRNAs in D. Data represents mean values of two patient and two control datasets.
G Transcription profiles of the SCPS2 gene. RNAseq and RT-PCR obtained concordant results showing relatively poor U12-type splicing in patients with increased intron
retention (U12 and flanking U2 introns), along with alternative (aberrant) U2-type splicing (~30% of transcripts). The alternative transcripts are barely present in
controls or heterozygous carriers. The band in genomic DNA lane (gDNA) is derived from a processed pseudogene on chromosome 1. Verification of the appropriate
content (real processed mRNA in the cDNA products and processed pseudogene in the genomic amplification) was performed by sequencing.
Source data are available for this figure.
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Splicing efficiency of 15 genes was studied by RT-PCR (Supple-
mentary Table 3). Consistent with RNAseq data, RT-PCR validated
the relative increase in abnormal processing of U12 introns in
patient cells. The relative levels of unspliced or aberrantly spliced
U12-type introns varied from <5 to 30% of the spliced mRNA
level.
Defects in genes related to pituitary-specific expression
A subset of genes with aberrant U12-type intron processing in the
IGHD patients encodes proteins with relevant functions in pituitary
development, thus becoming candidates for the phenotype. SPCS2
encodes an inferred protein subunit of the signal peptidase com-
plex implicated in posttranslational processing of preprohormones,
including preproghrelin processing to proghrelin (GO: 0005787; Yin
et al, 2009). Two novel transcripts, representing approximately
30% of SPCS2 mRNAs in IGHD cases but barely detected in con-
trols, result from partial activation of cryptic U2-type splice sites
instead of normal U12-splicing of the third intron (Fig 3G). One
transcript encodes a protein with 69 amino acids deleted in the
functional domain. The other has a frameshift leading to premature
truncation or NMD. Slightly increased intron retention and
alternative transcripts were also observed in the SPCS3 gene that
encodes another subunit of the same complex (Supplementary
Fig 1).
ARPC5L encodes an Arp2/3 complex protein that participates
in actin polymerization and is expressed in embryonic anterior
pituitary (Ma et al, 2009). Defective processing of the U12-type
intron leads to activation of nearby cryptic U2-type sites, almost
exclusive to IGHD patients, and a transcript encoding a protein
with an internal deletion of 27 amino acids (Supplementary
Fig 2).
Discussion
Pituitary development depends on a complex cascade of transcrip-
tion factors and signaling molecules that dictate organ commit-
ment, cell differentiation and cell proliferation. The most common
consequence of an abnormality in these processes is IGHD, as
GH-producing cells constitute 30–40% of anterior pituitary cells.
GHD has been linked so far to mutations in genes involved in GH
synthesis, function and regulation, or in pituitary development
(Pf€affle et al, 2011).
We identified biallelic mutations in the RNPC3 gene coding
for the minor spliceosome U11/U12-65K protein as a novel
mechanism associated with IGHD and pituitary hypoplasia in
three cases from a single family. U11/U12-65K protein levels are
strictly regulated (Verbeeren et al, 2010), as it is an essential
component of the intron-recognition complex (U11/U12 di-
snRNP) in the ubiquitous minor spliceosome (Benecke et al,
2005) involved in splicing of approximately 700 target genes.
The U11/U12-65K protein has dual binding activity, interacting
directly with U12 snRNA via its C-terminal RRM and with the
U11-associated 59K protein via its N-terminus (Will & L€uhrmann,
2005; Turunen et al, 2013). These interactions are necessary for
correct di-snRNP structure formation and intron recognition
(Frilander & Steitz, 1999; Benecke et al, 2005). The mutations
found here affect the second RRM motif of the 65K protein
with consequential defects in U11/U12 di-snRNP assembly
and splicing of a subset of U12-type introns, indicating that
minor splicesome dysfunction can lead to pituitary hypoplasia
and GHD.
These are the first reported patients with GHD due to aber-
rant mRNA processing, as well as the first pathology described
to be associated with a mutation in a protein of the minor
spliceosome. It is, however, the second example of a minor
spliceosome component associated with human disease. Muta-
tions in the U4atac snRNA component cause the severe form of
MOPD1/TALS (Edery et al, 2011; He et al, 2011). In this disease,
usually lethal in early childhood, patients have short bowed long
bones, cerebral cortex malformations, dry skin and sparse hair.
The phenotype of patients with RNPC3 mutations is much less
severe as growth failure, although severe, was postnatal. Brain
size was spared with no malformation except for pituitary
hypoplasia, and psychomotor development was normal with no
other organ failure. Interestingly, U4atac snRNA levels were
elevated in IGHD cells, suggesting a possible compensatory, yet
hitherto unknown, mechanism to reduce the effect of the
mutations.
Given the ubiquitous function of the minor spliceosome in all
cell types, the pathological differences between IGDH and
MOPD1/TALS, particularly the tissue-specificity, most likely relate
to differences in splicing defect severity. Transcriptome data is
unavailable for MOPD1/TALS, but the underlying defect is sug-
gested to be perturbation of multiple transcripts containing U12-
type introns that regulate global cell proliferation (Edery et al,
2011; He et al, 2011). In contrast, the defect in the IGHD patients
lead to a relatively low level of aberrant splicing for most genes
containing U12-type introns. It is likely that the mild defects in
splicing are tolerated in most tissues but not during pituitary
development, as somatotrophs are specifically affected. Genes
involved in pituitary development that show processing defects in
patient cells include the signal peptidases (SPCS2 and SPCS3) and
ARPC5L.
Similar tissue-specific effects occur in other splicing-related
diseases. Spinal muscular atrophy and some forms of retinitis
pigmentosa display tissue-specific phenotypes due to mutations
affecting both spliceosomes and the processing of numerous tran-
scripts in all cell types (Boulisfane et al, 2011; Linder et al, 2011).
These tissue-restricted effects could result from defective splicing
events of a few specific genes or from differential tissue sensitivity
to the aberrant processing of numerous transcripts (Cooper et al,
2009).
While individuals with complete GHD caused by loss of
function GH1 gene mutations often develop antibodies to
exogenous GH (Perez Jurado et al, 1997; Pf€affle et al, 2011),
patients with RNPC3 mutations showed excellent response and
immune tolerance to GH replacement. The explanation may be
that the GH1 gene is intact, displaying normal expression
and processing in blood cells despite the lack of pituitary
GH secretion.
In summary, our findings provide novel insights into the molecu-
lar basis of a new form of IGHD and demonstrate a crucial role of
the minor spliceosome in the processing of genes required for pitui-
tary development and GH synthesis.
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Materials and Methods
Genetic studies
The study was approved by the Hospital Infantil Universitario Ni~no
Jesus research ethics board and parents provided written informed
consent. This study complied with the WMA Declaration of Helsinki
and NIH Belmont report.
Deletions at the GH1 locus were discarded by previously estab-
lished methods (Perez Jurado et al, 1997). To perform linkage and
segregation analysis with known loci involved in GH deficiency, we
genotyped two microsatellites per locus (located at <500 Kb) in all
six nuclear family members. DNA was amplified using standard
conditions and a labeled PCR primer. PCR products were electro-
phoresed in an ABI PRISM 377 automated sequencer and analyzed
with fragment analysis software (Life Technologies). Genotyped loci
were: D17S944 and D17S949 (for GH1), D20S870 and D20S107 (for
GHRH), D7S632 and D7S526 (for GHRHR), D3S671 and D3S2386
(for POU1F1), D5S2008 and D5S2073 (for PROP1).
We then used whole-exome sequencing to search for mutations
in the DNA sample of proband IGHD1-01 using the Nimblegene
44 Mb capture kit and Illumina HiSeq 2000 sequencing. Sequences
were aligned to the NCBI build 37 human genome reference using
BWA. Duplicates were removed using Picard. Alignments were
recalibrated using GATK. Lane-level indel realignments and base
alignment quality adjustments were applied. In addition to the pub-
licly available 1000 genomes (www.1000genomes.org) and the 6503
samples from the exome variant server (gs.washington.edu/evs),
we checked exome data from 300 Spanish individuals to confirm the
absence of the mutations in all the controls. PCR with exon specific
primers and Sanger sequencing of the amplicons were performed
for validation. Primer sequences are available upon request.
For functional and expression studies, a lymphoblastoid cell line
was generated from the two older affected sisters using standard
protocols. Total RNA was isolated from mononuclear blood cells
and cell lines using standard methods.
Analysis of snRNAs and U11/U12 snRNPs
Integrity of U11/U12 di-snRNP complexes was analyzed using
native gel analyses (Frilander & Meng, 2005), glycerol gradient sedi-
mentation of lymphoblastoid cell lysates (Will et al, 2004) and via
pull-down assays. Nuclear lymphoblastoid cell extracts were
prepared as described earlier (Dignam et al, 1983). Whole cell
extracts from the same cells were prepared by dissolving cell pellets
in non-denaturing lysis buffer (20 mM tris-HCl, pH 8; 137 mM NaCl;
10% glycerol; 1% NP40; 2 mM EDTA), followed by sonication on ice
and clearing by centrifugation (16 000 g, 30 min). The resulting
supernatant was loaded on the top of a 10–30% glycerol gradient in
buffer (20 mM Hepes, pH 7.9; 100 mM KCl; 1 mM MgCl2) and
centrifuged (Sorvall TH641, 210 000 g (average), 16 h, +4°C) fol-
lowed by fractionation. Alternatively, the whole cell lysates were
incubated with 50 pmol biotinylated 2′-O-methyl RNA oligonucle-
tide complementary to U12 snRNA in 50 mM Hepes-KCl, pH 7.9,
100 mM KCl, 20 mM CRP, 0.5 mM ATP, 3 mM MgCl2, followed by
pull-down with 25 ll of streptavidin beads. After washing five times
with 20 volumes of washing buffer (50 mM Hepes-KCl, pH 7.9,
100 mM KCl, 3 mM MgCl2), the RNAs were isolated from pellet
fractions. Northern blot analysis was carried out as described earlier
(Pessa et al, 2006; Verbeeren et al, 2010). The data were collected
by phosphoimaging (Fuji FLA-5010) and analyzed with AIDA soft-
ware (Raytest, Germany).
Semi-quantitative RT-PCR analysis
Splicing efficiency of U12-type introns and alternative processing
was tested by RT-PCR analysis of total RNA. Total RNA from mono-
nuclear blood cells was treated with RQ1 RNase free DNase (Pro-
mega). First-strand cDNAs were synthesized from 2 lg of total RNA
using random hexamers and SuperScript II RT (BioRad). One-tenth
of the reaction was used in PCR [EcoTaq polymerase (Ecogen); 1x
Taq buffer containing 20 pmol of primers, 200 lm dNTP, 1.5 mm
MgCl2; 30 cycles]. We used intron-specific and exon-spanning
primers to quantify pre-mRNAs/mRNAs in which the intron under
investigation was either retained or spliced, respectively. Flanking
U2-type introns were included in each gene as an internal reference.
Primer sequences and PCR regimes and regions are shown in Sup-
plementary Table 3. The PCR products were separated on 1.5–3.5%
agarose gels containing ethidium bromide and visualized under UV
light. The gel images were digitally captured and analyzed using
BioRad software.
Transcriptome analyses
RNAseq was obtained from total RNA from mononuclear blood cells
of two patients (IGHD-01 and 02) and four control individuals of
normal stature and with no endocrine anomalies, by using Illumina
HiSeq 2000 sequencing generating paired reads 100 bp in length.
Sequences were aligned to the NCBI build 37 human genome refer-
ence using Bowtie 2 (http://bowtie-bio.sourceforge.net/bowtie2/
index.shtml). TopHat 2.0.4 (http://tophat.cbcb.umd.edu) was used
to map the inter-exon splice junctions. Cufflinks (http://cufflinks.
cbcb.umd.edu) was used to assemble the aligned RNAseq reads into
transcripts and estimate their abundance by quantifying the Frag-
ments Per Kilobase of transcript per Million fragments mapped
(FPKM value).
On average, 41.8 million mapped reads were obtained in cases
and 27.8 million reads in control samples. The integrative genome
viewer (IGV) application was used to visualize the data mapped by
Bowtie 2 and TopHat. Relative splicing efficiency of the U12-type
introns of the human genome was then quantified in cases and con-
trols (881 introns in 695 genes annotated in the U12 database,
U12DB, http://genome.crg.es/datasets/u12) (Alioto, 2007). We
quantified the split reads across exon junctions processed by U12
splicing, normalized with respect to the split reads across exon junc-
tions processed by two U2 splicing on the same genes and with
respect to the FPKMs per gene. Average U12/U2 and U12/FPKM
ratios per gene were established in each patient and control sample.
Intron retention was also quantified by examining the depth cover-
age of U12 intronic reads normalized with respect to the depth
coverage of two U2 intronic positions of the same gene as above
and with respect to the FPKMs per gene. Genes with high variability
in controls were discarded. By comparing cases and controls, a final
rank of genes showing significantly different values (above 2
standard deviations) in cases in at least two of the previous analyses
was established.
EMBO Molecular Medicine Defective mRNA processing and GH deficiency Jesus Argente et al
EMBO Molecular Medicine Vol 6 | No 3 | 2014 ª 2014 The Authors304
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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